Jaguar Health (NASDAQ:JAGX) Shares Gap Up to $1.49

Jaguar Health Inc (NASDAQ:JAGX) shares gapped up prior to trading on Wednesday . The stock had previously closed at $1.55, but opened at $1.49. Jaguar Health shares last traded at $1.28, with a volume of 12,480 shares trading hands.

JAGX has been the subject of several research reports. Zacks Investment Research cut shares of Jaguar Health from a “buy” rating to a “hold” rating in a research report on Thursday, August 15th. ValuEngine upgraded shares of Jaguar Health from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. HC Wainwright set a $10.00 price objective on shares of Jaguar Health and gave the company a “buy” rating in a research report on Tuesday, July 2nd. Finally, LADENBURG THALM/SH SH initiated coverage on shares of Jaguar Health in a research report on Thursday, September 12th. They issued a “buy” rating and a $5.00 price objective for the company.

The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.24 and a current ratio of 0.35. The stock has a market cap of $66.76 million, a price-to-earnings ratio of -0.01 and a beta of 0.74. The firm’s 50-day simple moving average is $1.29 and its two-hundred day simple moving average is $1.61.

Jaguar Health (NASDAQ:JAGX) last issued its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($9.09) EPS for the quarter, missing the consensus estimate of ($5.61) by ($3.48). Jaguar Health had a negative return on equity of 698.61% and a negative net margin of 727.27%. The business had revenue of $1.71 million for the quarter, compared to analyst estimates of $3.05 million. Equities research analysts expect that Jaguar Health Inc will post -4.81 earnings per share for the current fiscal year.

In other Jaguar Health news, Director James J. Bochnowski purchased 180,582 shares of the stock in a transaction dated Tuesday, July 23rd. The stock was bought at an average price of $2.00 per share, for a total transaction of $361,164.00. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.81% of the stock is owned by insiders.

Jaguar Health Company Profile (NASDAQ:JAGX)

Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.

Featured Article: What is Compound Annual Growth Rate (CAGR)?

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with's FREE daily email newsletter.